Evidence map›Paper›PMID 29338071›Full record

ReviewCA: a cancer journal for clinicians2018

The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.

Pricivel M Carrera, Hagop M Kantarjian, Victoria S Blinder

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CA: a cancer journal for clinicians, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07410689 (SAFE.AI), which is not on this map. Cited by 544 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
544citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07410689 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer Care

TypeinterventionalSponsorUniversity of UtahRan2026 to 2027Enrolled60ConditionsCancer, Financial ToxicityArmsRule-Based Chatbot, Hybrid Chatbot
3 · Its place in the literature

Who cites it

544 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Time toxicity in cancer care: a systematic review of definitions and measurement methods.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Towards the assessment of financial distress among cancer patients: a conceptual model of the financial effects of a tumour disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  7. The Role of Estrogen Receptor-Targeted PET with 16α-Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Pooled it
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Measures of financial toxicity in cancer survivors: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

484 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pricivel M CarreraAssistant Professor, Health Technology and Services Research, University of Twente, Enschede, The Netherlands.ORCID 0000-0001-6430-2858
Hagop M KantarjianProfessor and Chairman, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1908-3307
Victoria S BlinderMedical Oncologist, Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

"Financial toxicity" has now become a familiar term used in the discussion of cancer drugs, and it is gaining traction in the literature given the high price of newer classes of therapies. However, as a phenomenon in the contemporary treatment and care of people with cancer, financial toxicity is not fully understood, with the discussion on mitigation mainly geared toward interventions at the health system level. Although important, health policy prescriptions take time before their intended results manifest, if they are implemented at all. They require corresponding strategies at the individual patient level. In this review, the authors discuss the nature of financial toxicity, defined as the objective financial burden and subjective financial distress of patients with cancer, as a result of treatments using innovative drugs and concomitant health services. They discuss coping with financial toxicity by patients and how maladaptive coping leads to poor health and nonhealth outcomes. They cover management strategies for oncologists, including having the difficult and urgent conversation about the cost and value of cancer treatment, availability of and access to resources, and assessment of financial toxicity as part of supportive care in the provision of comprehensive cancer care. CA Cancer J Clin 2018;68:153-165. © 2018 American Cancer Society.

Indexed as

Cost of IllnessHealth Care CostsAntineoplastic AgentsFinancing, PersonalHealth PolicyHumansNeoplasmsStress, PsychologicalAntineoplastic Agentsantineoplastic agentscosts and cost analysisdecision makinghealth financingoncologistsprecision medicinereferral and consultationsupportive care

Identifiers

PMID29338071
PMCPMC6652174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.